Basics Aclaris Therapeutics, Inc. Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. IPO Date: October 7, 2015 Sector: Healthcare Industry: Biotech Market Cap: $316.37M Activated in VL: True Average Daily Range Avg Daily Range: $0.34 | 3.19% Avg Daily Range (30 D): $0.10 | 4.25% Avg Daily Range (90 D): $0.07 | 3.45% Institutional Daily Volume Avg Daily Volume: .68M Avg Daily Volume (30 D): 1.2M Avg Daily Volume (90 D): 1.06M Trade Size Avg Trade Size (Sh.): 153 Avg Trade Size (Sh.) (30 D): 155 Avg Trade Size (Sh.) (90 D): 182 Institutional Trades Total Inst.Trades: 1,171 Avg Inst. Trade: $1.57M Avg Inst. Trade (30 D): $1.01M Avg Inst. Trade (90 D): $1M Avg Inst. Trade Volume: .14M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.5M Avg Closing Trade (30 D): $1.44M Avg Closing Trade (90 D): $1.44M Avg Closing Volume: 143.25K     News Nov 25, 2025 @ 1:00 PM Aclaris Therapeutics to Participate in the Piper S... Source: Will Roberts Sep 9, 2025 @ 11:00 AM Aclaris Therapeutics Announces Late-Breaking Abstr... Source: Aclaris Therapeutics Aug 27, 2025 @ 12:00 PM Aclaris Therapeutics to Participate in Two Septemb... Source: Will Roberts May 9, 2025 @ 11:00 AM Aclaris Therapeutics to Participate in the HC Wain... Source: N/A Apr 29, 2025 @ 11:00 AM Aclaris Therapeutics Appoints Jesse Hall, M.D. as ... Source: N/A Financials   TTM Q3 2025 Q2 2025 Basic EPS $-1.58 $-.12 $-.13 Diluted EPS $-1.58 $-.12 $-.13 Revenue $ 15.74M $ 3.3M $ 1.78M Gross Profit $ 13.48M $ 2.76M $ 1.26M Net Income / Loss $ -141.68M $ -14.61M $ -15.43M Operating Income / Loss $ -153.32M $ -17.15M $ -18.41M Cost of Revenue $ 2.26M $ .54M $ .52M Net Cash Flow $ -22.4M $ -.15M $ -4.96M PE Ratio